Achaogen's Patient Enrollment In Final Stage EPIC Registration Trial Of Plazomicin Reaches 50%
June 02, 2016 at 09:44 AM EDT
Achaogen, Inc. (NASDAQ: AKAO) disclosed that it achieved more than 50 percent patient enrollment in its ongoing final stage EPIC ...
